Repligen $RGEN

Health Care · NASDAQ

$163.81
-6.48 (-3.81%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 29, 2026, the first target we tracked for RGEN.

Repligen (RGEN) is trading down at $163.81 (-3.81%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on RGEN

One firm's current price target on Repligen: $225 — 37% above the current $164. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateSep 29, 2026 FirmUBS RatingBuy · reiterates Targetat $195 · $225 +16% Horizonby Sep 2027 StatusOpen

Entry price $195, the close nearest Sep 29, 2026, when the target was reported; the target is +16% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.

Scoring Open: judged on the close on Sep 29, 2027.

Source Repligen stock price target reaffirmed at $225 by UBS on growth outlook Investing.com · Sep 29, 2026 · opens the publisher's site
Repligen stock price target reaffirmed at $225 by UBS on growth outlook

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Repligen revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$801.5M$388.0M−$25.5MFY2016 revenue: $104.5MFY2016 net income: $11.7M · Net margin 11.2%'16FY2017 revenue: $141.2MFY2017 net income: $28.4M · Net margin 20.1%'17FY2018 revenue: $194.0MFY2018 net income: $16.6M · Net margin 8.6%'18FY2019 revenue: $270.2MFY2019 net income: $21.4M · Net margin 7.9%'19FY2020 revenue: $366.3MFY2020 net income: $59.9M · Net margin 16.4%'20FY2021 revenue: $670.5MFY2021 net income: $128.3M · Net margin 19.1%'21FY2022 revenue: $801.5MFY2022 net income: $186.0M · Net margin 23.2%'22FY2023 revenue: $632.4MFY2023 net income: $35.6M · Net margin 5.6%'23FY2024 revenue: $634.4MFY2024 net income: −$25.5M · Net margin −4.0%'24FY2025 revenue: $738.3MFY2025 net income: $48.9M · Net margin 6.6%'250%20%40%60%FY2016 net margin: 11.2%FY2017 net margin: 20.1%FY2018 net margin: 8.6%FY2019 net margin: 7.9%FY2020 net margin: 16.4%FY2021 net margin: 19.1%FY2022 net margin: 23.2%FY2023 net margin: 5.6%FY2024 net margin: −4.0% (off the scale, which stops at −1.9%)FY2025 net margin: 6.6%
Repligen annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$104.5M$141.2M$194.0M$270.2M$366.3M$670.5M$801.5M$632.4M$634.4M$738.3M
Growth (year over year)+25.1%+35.1%+37.4%+39.3%+35.5%+83.1%+19.5%−21.1%+0.3%+16.4%
Gross profit$57.4M$74.2M$107.5M$151.1M$209.6M$391.3M$455.7M$278.4M$274.6M$386.2M
Gross margin54.9%52.5%55.4%55.9%57.2%58.3%56.9%44.0%43.3%52.3%
Operating income$16.0M$14.0M$26.0M$36.1M$69.8M$167.2M$224.7M$47.7M−$35.1M$55.2M
Operating margin15.3%9.9%13.4%13.4%19.1%24.9%28.0%7.5%−5.5%7.5%
Net income$11.7M$28.4M$16.6M$21.4M$59.9M$128.3M$186.0M$35.6M−$25.5M$48.9M
Net margin11.2%20.1%8.6%7.9%16.4%19.1%23.2%5.6%−4.0%6.6%
EPS (diluted)$0.34$0.72$0.37$0.44$1.11$2.24$3.24$0.63−$0.46$0.86
Balance sheet
Cash and equivalents$122.2M$173.8M$193.8M$528.4M$717.3M$603.8M$523.5M$751.3M$757.4M$566.0M
Total assets$288.9M$743.5M$774.6M$1.40B$1.90B$2.36B$2.53B$2.83B$2.83B$2.95B
Total liabilities$120.1M$152.0M$159.1M$340.3M$373.7M$608.3M$620.9M$866.3M$856.9M$843.6M
Long-term debt————————$525.6M$542.2M
Shareholders' equity$168.8M$591.5M$615.6M$1.06B$1.53B$1.75B$1.91B$1.96B$1.97B$2.11B
Cash flow
Operating cash flow$7.52M$17.5M$32.8M$67.2M$62.6M$119.0M$172.1M$113.9M$175.4M$117.4M
Capital expenditure$4.33M$5.45M$10.6M$18.5M$22.5M$67.1M$84.8M$36.2M$25.7M$23.5M
Free cash flow$3.20M$12.0M$22.1M$48.7M$40.2M$51.9M$87.2M$77.7M$149.7M$93.9M
Share buybacks—————$0$0$14.4M$0$0

From Repligen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Repligen in the news

Nov 18, 2026 Investing.com Repligen at Jefferies Global Healthcare Conference: eyeing a 2027 rebound
Sep 29, 2026 Investing.com Repligen stock price target reaffirmed at $225 by UBS on growth outlook Target
Aug 26, 2026 GlobeNewswire Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference

About Repligen

Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.

Source: Wikipedia — Repligen

Headquarters
Waltham, Massachusetts From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →